These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18378531)

  • 1. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone, a new treatment option for metastatic breast cancer.
    Toppmeyer DL; Goodin S
    Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
    Perez EA
    Breast Cancer Res Treat; 2009 Mar; 114(2):195-201. PubMed ID: 18443902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies with epothilones for the treatment of metastatic breast cancer.
    Vahdat LT
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixabepilone for the treatment of breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of epothilones in breast cancer therapy.
    Cianfrocca M
    Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M
    Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
    Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
    J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
    Cigler T; Vahdat L
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixabepilone.
    Stein A
    Clin J Oncol Nurs; 2010 Feb; 14(1):65-71. PubMed ID: 20118028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
    Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
    J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.